Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

Anesthesia-associated mortality rises again

In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.

22 Jul 2011

Neovasc to fund Tiara project with $4 million private placement

Neovasc Inc. today announced that it intends to complete a non-brokered private placement with accredited investors of up to four million equity units at the price of $1.00 per unit for aggregate gross proceeds of up to $4.0 million. The company expects that insiders will purchase approximately half of the units.

21 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

FDA approves Brilinta to reduce cardiovascular death and heart attack in ACS patients

The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta (ticagrelor) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS).

21 Jul 2011

AstraZeneca receives FDA approval for BRILINTA to treat acute coronary syndrome

AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.

21 Jul 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta

The U.S. Food and drug Administration (FDA) has finally approved AstraZeneca's Brilinta blood thinner for patients with acute coronary syndrome - conditions, such as heart attack and angina.

20 Jul 2011

Autologous adult stem cells reduce frequency of angina episodes

New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).

From Baxter International Inc. 8 Jul 2011

Study: More PCIs classified as appropriate for acute indications in the U.S.

In an examination of the appropriateness of the widespread use of percutaneous coronary interventions (PCIs), researchers found that of more than 500,000 PCIs included in the study, nearly all for acute indications were classified as appropriate, whereas only about half of PCIs performed for nonacute indications could be classified as appropriate, according to a study in the July 6 issue of JAMA.

6 Jul 2011

Life satisfaction protects against coronary heart disease

While depression and anxiety have long been recognised as risk factors for heart disease, there is less certainty over the beneficial effects of a 'positive' psychological state, Now, following a study of almost 8000 British civil servants, researchers say that a satisfying life is indeed good for the heart.

5 Jul 2011

New clot busting drug approved in UK

The National Institute for Clinical Excellence (Nice), UK, has approved a new drug which one study has suggested could reduce the risk of death from a second heart attack by 20 per cent. The drug is manufactured by AstraZeneca as Brilique. It works by maintaining cardiac blood flow and stopping new blood clots from forming.

1 Jul 2011

Maternal smoking 'imprints' unhealthy set of characteristics on unborn babies

Researchers in Australia have discovered that mothers who smoke during pregnancy are causing developmental changes to their unborn babies that lead to them having lower levels of the type of cholesterol that is known to protect against heart disease in later life - high-density lipoprotein (HDL) cholesterol.

22 Jun 2011

Neovasc first quarter revenues increase 10% to $1,169,920

Neovasc Inc., today announced financial results for the three months ended March 31, 2011 and advances in its product development programs.

20 Jun 2011

Cholesterol-lowering statins reduce rate of mortality and cardiovascular events

Over the long term, treatment with cholesterol-lowering statins reduces the rate of mortality and cardiovascular events such as heart attack, for people with and without heart disease. Still, it is unclear whether these drugs take effect rapidly when the risk of these dire events is highest.

15 Jun 2011

ESC publishes position paper to raise the profile of vulnerable plaques

The European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology has published a position paper to raise the profile of vulnerable plaques and the need for greater use of therapies to promote plaque stabilisation.

15 Jun 2011

Milestone completes $13 million round of equity financing

Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing.

13 Jun 2011

Researchers explore relationship between emotions and poor prognosis in heart disease

Intense distress and fear of dying, which many people experience when suffering the symptoms of a heart attack, are not only fairly common emotional responses but are also linked to biological changes that occur during the event, according to new research published online today in the European Heart Journal.

2 Jun 2011

Asymptomatic patients do not benefit from CT angiography screening

Coronary computed tomographic angiography, which can detect plaque buildup in heart vessels, is sometimes used as a screening tool to assess the risk for a heart attack. However, the usefulness of the test on low-risk patients who do not have coronary symptoms, such as chest pain, has been unclear.

24 May 2011

Sensitive troponin assays improve clinical outcome and cardiac patient management

Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.

19 May 2011

CryoLife acquires Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.

17 May 2011

Many herbal medicines banned under EU directives

According to the new EU rules that came into force over the weekend, hundreds of herbal remedies are now banned. The laws are aimed at protecting consumers from potentially damaging “traditional” medicines.

1 May 2011